HUMIRA and Psoriatic Arthritis

HUMIRA helps to reduce the joint pain and skin symptoms of Psoriatic Arthritis as well as inhibit the progression of joint damage.

Create Possibilities*

HUMIRA and Psoriatic Arthritis

HUMIRA helps to reduce the joint pain and skin symptoms of Psoriatic Arthritis as well as inhibit the progression of joint damage.

If you’re still experiencing Psoriatic Arthritis symptoms despite being on treatment, HUMIRA may be able to help.

What is Psoriatic Arthritis?

Psoriatic Arthritis is an inflammatory disease that occurs when your immune system mistakenly starts attacking healthy joints and skin.

Find out more about Psoriatic Arthritis

HUMIRA Safety Information

Safety information on this website includes some of the more important information to know about HUMIRA.

HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Psoriatic Arthritis.

Taking HUMIRA

What you need to know about taking HUMIRA, including helping you get the best out of your HUMIRA treatment.

Talk with your doctor

Your rheumatologist can answer any questions you may have and provide additional information and support.

# All experiences, possible outcomes or improvements are hypothetical and based on significant clinical and Quality Of Life (QOL) improvements as measured in the listed clinical studies following HUMIRA treatment. Use of this statement does not imply endorsement or approval by the author.
*AbbVie medications and programmes are designed to support patients on their health journey.
References:

Health Navigator website: Psoriatic arthritis; https://www.healthnavigator.org.nz/health-a-z/p/psoriatic-arthritis/ Accessed December 2019
HUMIRA Approved Consumer Medical Information.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.

HUMIRA and Psoriatic Arthritis

Create Possibilities*

Create Possibilities*

HUMIRA and Psoriatic Arthritis

What is Psoriatic Arthritis?

Find out more about Psoriatic Arthritis

Find out more

HUMIRA Safety Information

How does HUMIRA work?

Taking HUMIRA

Talk with your doctor

Cancel